Build the model around days supplied and who pays—not the advertised monthly headline. The examples below are analyst calculations prepared November 17, 2026, not observed network averages or forecasts.
Why does a four-week supply change the budget?
At a constant $449 per 28-day fill, 13 fills cost $5,837 and provide 364 days of supply. Twelve fills cost $5,388 but provide only 336 days. Moving from the twelve-fill assumption to thirteen raises that budget by $449, or 8.33%. These calculations use Lilly’s published offer price and supply definition; they assume continued eligibility and unchanged pricing. Lilly terms
Do not extend that calculation automatically to a telehealth subscription. Its contractual billing and supply definitions must first be reconciled.
What expenditure could an individual network influence?
The following constant-price sensitivity uses 13 four-week fills at the published $349 standard Wegovy or $449 conditional Zepbound benchmarks. It assumes every hypothetical patient remains active throughout the period, with unchanged price and eligibility. It excludes introductory offers, subscriptions, care charges and operational costs. Wegovy price basis; Zepbound price basis
| Hypothetical continuously active patients | At $349 × 13 fills | At $449 × 13 fills |
|---|---|---|
| 1,000 | $4.537 million | $5.837 million |
| 5,000 | $22.685 million | $29.185 million |
| 10,000 | $45.370 million | $58.370 million |
Formula: active patients × price per fill × 13. These are alternative expenditure illustrations, not clinically equivalent treatment choices or a recommended switching strategy. They are also not a 2027 price forecast, given the documented offer expirations and change rights.
The clinic may influence this expenditure without collecting it. Conversely, arrangements involving an owned pharmacy can alter revenue presentation: LifeMD stated in its November 12, 2026 results that branded medicines fulfilled by its pharmacy were recognized on a gross revenue basis. That is a useful warning against comparing clinic margins without reconciling business models. LifeMD results
What should the GLP-1 clinic cost model contain?
Use three separate outputs:
- Patient access cost: medicine plus patient-paid care, membership and delivery charges.
- Clinic-controlled cost: purchasing, service fees, internal handling and other costs actually borne by the provider.
- Cash and commitment exposure: deposits, stock, minimum purchases, prepaid periods and termination obligations.
For operational comparison, the desk proposes:
Cost per successfully fulfilled patient-month = costs allocated to the measurement period ÷ patient-months meeting the agreed fulfillment definition.
Define fulfillment before comparing suppliers—for example, expected clinician-authorized supply delivered within the agreed window. Report delivery failures, refunds and unfilled prescriptions alongside the ratio so that excluding unsuccessful cases does not hide poor performance. This measures fulfillment, not clinical success.
Explore the table row by row
A working view of the research
1,000
- At $349 × 13 fills
- $4.537 million
- At $449 × 13 fills
- $5.837 million
Sources cited on this page
- zepbound.lilly.com · Source 1 ↗https://zepbound.lilly.com/hcp/coverage-savings
- novocare.com · Source 2 ↗https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- sec.gov · Source 3 ↗https://www.sec.gov/Archives/edgar/data/948320/000149315226051397/ex99-1.htm